Imidafenacin

Summary

Imidafenacin (CHEMBL53366) is a phase-3 clinical-stage small molecule (ATC G04BD14); indicated across 3 conditions including overactive bladder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: G04BD14
• Indications: 3 conditions
• Clinical trials: 7
• Chemistry: 319.4 Da · C20H21N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL53366
Name	Imidafenacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6433090
ATC	G04BD14
Molecular formula	C20H21N3O
Molecular weight	319.4
InChIKey	SQKXYSGRELMAAU-UHFFFAOYSA-N

SMILES: CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N

IUPAC name: 4-(2-methylimidazol-1-yl)-2,2-diphenylbutanamide

Also known as: Imidafenacin, Imidafenacina, Imidafenacine, KRP-197, ONO-8025, Staybla, Uritos, IMIDAFENACIN, ImidafenacinÊ, ImidafenacinÂ

Patent coverage: 97 distinct patent families (239 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
overactive bladder	3	MONDO:0006624	EFO:1000781

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	2
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01578304	PHASE4	COMPLETED	Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
NCT02294396	PHASE4	COMPLETED	Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
NCT00212732	PHASE3	COMPLETED	Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
NCT00512785	PHASE3	COMPLETED	Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder
NCT00212706	PHASE2	COMPLETED	Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
NCT03572231	Not specified	COMPLETED	A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03602508	Not specified	COMPLETED	Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).